mylife CamAPS FX app is now available on iOS across the UK, expanding access to type 1 diabetes technology

People living with type 1 diabetes (T1D) across the UK now have more choice in how to manage their condition with the mylife CamAPS FX app now available on iPhones, as the latest version of the app launches on iOS.

The CamAPS FX app works as part of a hybrid closed-loop system. These systems use an algorithm to take readings from a continuous glucose monitor (CGM) and uses these data to tell a connected insulin pump how much insulin to deliver. This can help to relieve some of the burden of managing type 1 diabetes, by adjusting and automating insulin delivery in real time according to a person’s glucose levels.

Previously, the CamAPS FX app was only available on android devices but following a successful pilot in Sweden earlier this year the app will now be available on iOS across the UK, Ireland, Germany, Denmark, Austria, Norway, Finland, and Luxembourg. The iOS rollout means that people have more flexibility and choice in how they manage their T1D.

Professor Roman Hovorka, CamAPS FX creator and Professor of Metabolic Technology at the Institute of Metabolic Science and Department of Paediatrics at the University of Cambridge, said:

“We are thrilled to bring the mylife CamAPS FX app to iOS users across the UK. This launch represents a significant step forward in making advanced, adaptive diabetes technology more accessible and convenient.”

Building on years of research

With support from Breakthrough T1D Professor Roman Hovorka, and his team at the University of Cambridge, began developing the CamAPS FX system in 2006. With early versions of the app being tested on laptops in hospital settings. Over time, clinical studies showed that the technology could safely be used at home without clinical supervision. These studies helped pave the way for its regulatory approval and real-world use.

In 2020, the CamAPS FX app became the first licensed app of its kind for managing T1D in both young children and during pregnancy, two groups that historically have had limited access to automated diabetes technology.

The system works with the mylife YpsoPump and is compatible with popular CGMs including FreeStyle Libre 3, Libre 3 Plus, and Dexcom G6. It is approved for people with type 1 diabetes from 1-year old, including during pregnancy, depending on the sensor used.

A breakthrough for NHS access

In recent years, Breakthrough T1D has helped advance national access to this technology. In 2023, the National Institute for Health and Care Excellence (NICE) published final guidance recommending that hybrid closed-loop systems be funded by the NHS for:

• All children and young people
• People who are pregnant or planning pregnancy
• Adults with an HbA1c of 7.5% or higher
• People with severe hypoglycaemia despite optimal management

These recommendations followed extensive clinical evidence and public advocacy, much of which stemmed from Professor Hovorka’s research.

Professor Partha Kar, Type 1 Diabetes and Tech lead for NHS England and GIRFT, welcomed the iOS release, saying:

“The launch of CamAPS FX on iOS is an important step in expanding access to safe, evidence-based digital health solutions for people living with type 1 diabetes. It also reflects the UK’s position as a global leader in driving inclusive, tech-enabled healthcare through strong academic, clinical, and industry collaboration.”